Is AstraZeneca PLC (AZN) a risky stock?
As of July 21, 2026, Clavix grades AstraZeneca PLC (AZN) C+ for risk, a composite score of 59 out of 100 on an A+ to F scale, which puts AZN in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind AZN's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how AZN scores on each, as of July 21, 2026.
What's moving AZN's risk right now
Company-specific signals Clavix flags behind AZN's current grade, drawn from recent news and filings as of July 21, 2026.
This stock has handily outperformed the S&P 500 index, but has its ties to artificial intelligence turned it into a risky investment? Caterpillar (NYSE: CAT) is an iconic name in…
CAT outpaces VLVLY with stronger earnings trend, rising estimates and long-term growth targets despite tariff headwinds. Which stock stands out?
Caterpillar is capitalizing on the artificial intelligence (AI) boom. Caterpillar (NYSE: CAT) is up 265% in the last three years, largely thanks to the artificial intelligence (AI…
What a C+ grade means
On the Clavix A+ to F scale, AZN's composite of 59 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell AZN or any security. Grades are risk indicators, not predictions of return. Data may be delayed.